Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 08 04 2022
accepted: 30 05 2022
entrez: 11 7 2022
pubmed: 12 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

People with HIV (PWH) are at increased risk of developing active tuberculosis (TB), and anemia is a common complication in both conditions. Anemia in TB patients has been linked to immune activation, levels of inflammatory biomarkers in blood, and risk for HIV disease progression and death. In this study we show that anemia was associated with a more pronounced inflammatory profile in HIV-TB coinfected persons in a cohort of 159 individuals with advanced HIV disease (CD4 count < 100 cells/µL) recruited as part of a randomized clinical trial (NCT00988780). A panel of plasma biomarkers was assessed on plasma obtained prior to combination antiretroviral therapy (cART) initiation. We performed a series of multidimensional analyses including clinical variables and concentrations of inflammatory biomarkers to profile systemic inflammation of PWH with and without anemia. We observed that TB participants presented with moderately lower levels of hemoglobin than non-TB participants. These participants also presented a higher Degree of Inflammatory Perturbation (DIP) score, related to increased levels of IFN-γ and TNF. The DIP was associated with TB coinfection and anemia before cART initiation. Future mechanistic studies are warranted to assess the determinants of such associations and the implications on treatment outcomes.

Identifiants

pubmed: 35812431
doi: 10.3389/fimmu.2022.916216
pmc: PMC9260499
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT00988780']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

916216

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI115940
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States

Informations de copyright

Copyright © 2022 Araújo-Pereira, Barreto-Duarte, Arriaga, Musselwhite, Vinhaes, Belaunzaran-Zamudio, Rupert, Montaner, Lederman, Sereti, Madero and Andrade.

Déclaration de conflit d'intérêts

JS-M reports grants from BMS, Pfizer, MSD, and Stendhal outside the submitted work. LJM reports grants from Merck and Gene-One. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Immunol. 2007 Nov 15;179(10):6973-80
pubmed: 17982088
J Infect Dis. 2021 Apr 8;223(7):1275-1283
pubmed: 32761193
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Front Genet. 2019 Oct 24;10:971
pubmed: 31708960
Int J Med Sci. 2019 Jan 1;16(2):276-284
pubmed: 30745808
Clin Microbiol Rev. 2011 Apr;24(2):351-76
pubmed: 21482729
PLoS One. 2015 Feb 26;10(2):e0117424
pubmed: 25719208
J Immunol Methods. 2012 Jan 31;375(1-2):196-206
pubmed: 22075274
Cell Mol Immunol. 2017 Dec;14(12):960-962
pubmed: 29082920
J Infect Dis. 2011 Jun 1;203(11):1637-46
pubmed: 21592994
Front Immunol. 2020 Sep 24;11:588405
pubmed: 33072136
J Biomed Sci. 2009 Nov 18;16:102
pubmed: 19922646
Lancet HIV. 2014 Nov;1(2):e60-7
pubmed: 26423989
Sci Rep. 2019 Feb 4;9(1):1381
pubmed: 30718725
Rev Med Virol. 2003 Jan-Feb;13(1):39-56
pubmed: 12516061
AIDS. 1999 May 28;13(8):943-50
pubmed: 10371175
J Virus Erad. 2017 Jan 1;3(1):24-33
pubmed: 28275455
AIDS Res Hum Retroviruses. 2004 Oct;20(10):1037-45
pubmed: 15587490
Open Forum Infect Dis. 2019 Jan 31;6(2):ofz015
pubmed: 30800697
HIV Med. 2007 Jan;8(1):38-45
pubmed: 17305931
J Gen Intern Med. 1988 Sep-Oct;3(5):464-70
pubmed: 3262733
Int J Tuberc Lung Dis. 2011 Jul;15(7):925-32
pubmed: 21682966

Auteurs

Mariana Araújo-Pereira (M)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Programa de Pós-Graduação em Patologia Humana e Experimental, Universidade Federal da Bahia, Salvador, Brazil.

Beatriz Barreto-Duarte (B)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.

María B Arriaga (MB)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

Laura W Musselwhite (LW)

Department of Solid Tumor Oncology, Levine Cancer Institute, Charlotte, NC, United States.

Caian L Vinhaes (CL)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, Salvador, Brazil.

Pablo F Belaunzaran-Zamudio (PF)

Infectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Adam Rupert (A)

National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.

Luis J Montaner (LJ)

The Wistar Institute, Philadelphia, PA, United States.

Michael M Lederman (MM)

Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University, Cleveland, OH, United States.

Irini Sereti (I)

National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.

Juan G Sierra Madero (JGS)

Infectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Bruno B Andrade (BB)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Programa de Pós-Graduação em Patologia Humana e Experimental, Universidade Federal da Bahia, Salvador, Brazil.
Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
Bahiana School of Medicine and Public Health, Bahia Foundation for the Development of Sciences, Salvador, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH